Rhythm Biosciences scores leading biotech fund as new shareholder
Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.
In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.
The below articles were written under our previous business model. We have kept these articles online here for your reference.
Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.
Click Here to View Latest Articles
Medical diagnostics innovator, Rhythm Biosciences (ASX:RHY), has welcomed leading biotech investor, Merchant Group, as a major new shareholder.
The Merchant Opportunities Fund, which now holds 5.02 per cent of RHY, has long been recognised as a successful, long-term investor in biotech companies that are nearing commercialisation.
RHY CEO, Dr Trevor Lockett, said: “We are particularly happy to have Merchant as a substantial shareholder, given their enviable record of combining thorough research with exceptional returns.”
“That has been shown with many of their previous substantial shareholder investments in the biotechnology industry such as PolyNovo (ASX:PNV), where after almost 5 years, Merchant Group and the Merchant Opportunities Fund still maintains a substantial stake,” Lockett noted.
“We are confident that Merchant will be a supportive equity partner as we work diligently on commercialising the company’s simple and effective ColoSTATTM blood test for colorectal cancer.’’
Lockett said that RHY was in the process of preparing reagents for the ColoSTATTM blood test, which is the result of over a decade of research and development by RHY and CSIRO.
RHY’s ColoSTAT uses antibodies to measure the levels of several particular proteins in the blood, which have been shown to vary in the presence of absence of colorectal cancer. The concentration values are then combined using a proprietary algorithm, and this process provides an indication of cancer risk. A returned result above a certain threshold will be an indicator that a patient should progress to a colonoscopy for further investigation.
“Given that colorectal cancer is the second biggest cause of cancer death in the world, we are working as fast as we can to progress ColoSTAT so that it becomes an important tool in the early diagnosis and treatment of colorectal cancer, along with other existing tools such as the faecal immunochemical test (FIT) and colonoscopy,’’ Lockett said.
As always, it should be noted that RHY is an early stage play and anything can happen, so seek professional financial advice if considering this stock for your portfolio.
General Information Only
This material has been prepared by Jason Price. Jason Price is an authorised representative (AR 000296877) of 62 Consulting Pty Limited (ABN 88 664 809 303) (AFSL 548573) (62C), and a Director of S3 Consortium Pty Ltd (trading as StocksDigital).
This material is general advice only and is not an offer for the purchase or sale of any financial product or service. The material is not intended to provide you with personal financial or tax advice and does not take into account your personal objectives, financial situation or needs. Although we believe that the material is correct, no warranty of accuracy, reliability or completeness is given, except for liability under statute which cannot be excluded. Please note that past performance may not be indicative of future performance and that no guarantee of performance, the return of capital or a particular rate of return is given by 62C, Jason Price, StocksDigital, any of their related body corporates or any other person. To the maximum extent possible, 62C, Jason Price, StocksDigital, their related body corporates or any other person do not accept any liability for any statement in this material.
Conflicts of Interest Notice
S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.
Publication Notice and Disclaimer
The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.
Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.
This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.
